Completion of Inspection by United States Food and Drug Administration (USFDA) Of our API Facility At Dholka.
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The USFDA completed an inspection of Concord Biotech's API manufacturing facility at Dholka, Ahmedabad, from April 28 to May 2, 2025. At the end of the inspection, the USFDA issued a Form 483 with 4 observations. The company clarified that all 4 observations are procedural in nature and none relate to data integrity issues. Concord Biotech stated it will submit a detailed response to the USFDA within the required timeframe and is confident of addressing the observations quickly.
Form 483 observations are common during USFDA inspections and are not equivalent to a warning letter. Since the company has characterised them as procedural and not data integrity-related, the short-term impact on the stock may be limited, but investors should watch for the company's response and any follow-up action from the USFDA.